These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26082332)

  • 1. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
    Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
    Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
    Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
    Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
    Rajan A; Kelly RJ; Trepel JB; Kim YS; Alarcon SV; Kummar S; Gutierrez M; Crandon S; Zein WM; Jain L; Mannargudi B; Figg WD; Houk BE; Shnaidman M; Brega N; Giaccone G
    Clin Cancer Res; 2011 Nov; 17(21):6831-9. PubMed ID: 21908572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
    Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
    Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
    Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
    Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
    Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
    de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
    Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
    Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
    Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
    Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
    Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
    Slovin S; Hussain S; Saad F; Garcia J; Picus J; Ferraldeschi R; Crespo M; Flohr P; Riisnaes R; Lin C; Keer H; Oganesian A; Workman P; de Bono J
    Clin Cancer Res; 2019 Aug; 25(15):4624-4633. PubMed ID: 31113841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
    Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
    Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Riess JW; Reckamp KL; Frankel P; Longmate J; Kelly KA; Gandara DR; Weipert CM; Raymond VM; Keer HN; Mack PC; Newman EM; Lara PN
    Clin Lung Cancer; 2021 Nov; 22(6):541-548. PubMed ID: 34140248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.